Market Research

Prurigo Nodularis (PN)

Best Price Guarantee Length Publisher Published Date SKU
from $12,250 24 Pages Reach Market Research March, 2022 RMR19136511
Best Price Guarantee
Price from $12,250
Length 24 Pages
Publisher Reach Market Research
Published Date March, 2022
SKU RMR19136511

MarketVue®: Prurigo Nodularis (PN)

The MarketVue®: Prurigo Nodularis (PN) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Prurigo Nodularis (PN) report is supported by 4 qualitative interviews with key opinion leaders, a quantitative survey with 20 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Galderma
• Sanofi
• Menlo Therapeutics / Vyne Therapeutics
• Trevi Therapeutics
• Incyte
• Kiniksa
• Celldex Therapeutics

Key drugs mentioned:
• Methotrexate
• Gabapentin
• Dupilumab (Dupixent)
• Nemolizumab (Nemluvio)
• Nalbuphine HCl (Haduvio)
• INCB054707
• Vixarelimab
• CDX-0159
• Serlopitant
• INCB054707
• CDX-0159

Please note: the online download version of this report is for a global site license.


1. DISEASE OVERVIEW
A rare and chronic inflammatory condition causing itchy nodules on the skin
Figure 1.1 – “Itch-and-scratch” cycle
PN is largely an idiopathic condition
Figure 1.2 – Percentage of PN patients with idiopathic disease
Table 1.1 – Comorbidities associated with PN
Quality of life and psychosocial impact of PN on patients
Figure 1.3 – Percentage of patients experiencing various negative impacts of PN
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – G6 diagnosed prevalent cases of PN by region
Table 2.1 – Diagnosed prevalent and drug-treated populations of PN in the U.S. and EU5
PN diagnosis and drug-treatment rates are exceptionally high
Figure 2.2 – Dermatologist-reported segmentation of PN population by disease severity
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1 – Diagnostic journey for PN patients
Lack of FDA-approved treatments for PN
Treatment overview
Table 3.1 – Treatment goals for PN
Figure 3.2 – Dermatologists rating the effectiveness of and satisfaction with current PN therapies
Current treatments for PN
Figure 3.3 – Patient share and physician use of current treatments in PN
Table 3.2 – Upsides and downsides of current treatments used for PN
Current treatments for PN
Figure 3.4 – Percentage of dermatologists who treat PN and their PN patient load
Figure 3.5 – Treatment decision tree for PN
Dermatologists’ opinions on current treatments
Off-label Dupixent use to treat PN
Figure 3.6 – Treatment dynamics of Dupixent use in PN
Key treatment dynamics that shape disease management and drug use in PN
Table 3.3 – Must-know PN treatment dynamics for now and the future
Figure 3.7 – Percentage of PN patients that are eligible for a biologic or advanced systemic
New therapies for PN likely to arrive to the market as label expansions of current therapies
Figure 3.8 – Important dynamics of PN market evolution
4. UNMET NEEDS
Overview
Figure 4.1 – Top unmet needs in PN
Figure 4.2 – Dermatologist-reported unmet needs in PN
Physician perspectives on unmet needs in PN
Figure 4.3 – U.S. dermatologists’ ranking of the need for new treatments in dermatology
5. PIPELINE ANALYSIS
Figure 5.1 – Number of clinical stage therapies addressing unmet needs in PN
Figure 5.2 – Percentage of dermatologists selecting attribute among their top three influencers of treatment selection in PN
Dermatologists are excited about biologics and other mechanisms of action for PN
Table 5.1 – Dermatologists’ rating of how “promising” emerging therapies are on a scale of 1-7
Table 5.2 – Emerging PN therapies, Phase 1 to Phase 3
Dupixent and nemolizumab are out front and poised to compete for first-line biologic use in PN
Figure 5.3 – Differentiation between Dupixent and nemolizumab in PN
Figure 5.4 – Comparison of reduction of itch (WI-NRS) of pipeline agents in moderate-to-severe PN
6. VALUE & ACCESS
Overview
Figure 6.1. Commercial insurance restrictions on Dupixent’s use in atopic dermatitis
Figure 6.2. Dupixent monthly copay payments of Medicare and commercially-insured patients
7. METHODOLOGY
Primary market research approach
Epidemiology methodology

$12,250

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings